Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU And U.S. Regulators Toughen CV Monitoring Requirements For Novartis's Gilenya

This article was originally published in The Pink Sheet Daily

Executive Summary

A review of a potential association between Novartis's oral multiple sclerosis therapy Gilenya and sudden death was inconclusive, say EU regulators, but monitoring requirements are still strengthened as a precaution.

You may also be interested in...



EMA Passes GSK’s Mekinist, Extends Indications For Gilenya And Pradaxa

The EMA recommended authorizing a single drug this month, GSK’s Mekinist, while giving the nod to seven others, including Novartis’ Gilenya and Boehringer Ingelheim’s Pradaxa.

Novartis To Increase Marketing Support As New Products Drive Growth In The Second Quarter

Novartis highlights its under-appreciated new product portfolio as total sales increase by 1% in the second quarter, buffeted by adverse currency movements, generic competition to Diovan and enoxaparin, and manufacturing issues.

Sanofi Sets Sights On Multiple Sclerosis Leadership

With the release of “unprecedented” data on its Phase III MS candidate alemtuzumab and its once-daily oral therapy teriflunomide already under regulatory review, Sanofi looks for a leadership role in the increasingly fragmented market it expects will approach $20 billion by 2016.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074047

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel